Registry could be ‘invaluable’ for tracking long-term CAR T-cell therapy outcomes

The Center for International Blood and Marrow Transplant Research, through an alliance with Novartis, aims to track the long-term outcomes of patients treated with chimeric antigen receptor T-cell therapies.

The center will collect data from children and adults treated with tisagenlecleucel (Kymriah, Novartis) who agree to participate in the center’s cellular therapy registry.

“We are excited to announce this collaboration with Novartis, a pioneer in the field of immunocellular therapy,” Marcelo C. Pasquini, MD, MS, senior scientific director of Center for International Blood and Marrow Transplant Research (CIBMTR) and associate professor in the department of medicine at Medical College of Wisconsin, said in a press release. “This alliance will leverage CIBMTR’s deep experience collecting and analyzing data on both short- and long-term outcomes of complex cellular therapies.”

HemOnc Today spoke with Pasquini about how this collaboration came about, how the outcomes data tracked through this registry can be used to guide or inform patient treatment, and whether the research center plans to incorporate data related to the other chimeric antigen receptor (CAR) T-cell therapies, such as FDA-approved axicabtagene ciloleucel (Yescarta; Kite Pharma/Gilead).

Read more at: